-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Under the background of "double carbon", the photovoltaic industry has become a hot track in the field of new energy, and many listed companies are making cross-border layouts through investment and mergers and acquisitio.
According to industry statistics, no less than 20 companies have announced their entry into the photovoltaic industry since the beginning of this year, with an investment of tens of billions of yu.
There are also some pharmaceutical companies among th.
On August 4, Lvkang Biochemical, a pharmaceutical company in the cross-border photovoltaic industry, won the market's attention by winning the four-link boa.
As of the close on the 3rd, the stock's closing price was 180 yuan, and the stock price hit a new high in nearly 3 years that d.
On the news, on August 1, Lvkang Biochemical announced that it planned to acquire 100% of the equity of the loss-making company Jiangxi Weike at a premium of 632%, and then lay out the photovoltaic film indust.
According to the announcement, Lvkang Biochemical intends to purchase 100% equity of Jiangxi Weike held by Yushan Wanghong Enterprise Management Center (Limited Partnership) and Wang Meijun in cash, with an estimated asset value of 100 million yuan, a premium over its book net assets about 63
According to the data, Jiangxi Weike is mainly engaged in the research and development, production, sales and installation of thin-film composite materials and photovoltaic supporting componen.
The company will have a loss of 6374 million yuan in 2021 and a loss of 8863 million yuan from January to April 2022, with an asset-liability ratio of 9
According to the announcement, the estimated value of 100% equity of Jiangxi Weike is 100 million yuan, and the premium rate is about 63
Regarding the reason for this high premium acquisition, Lvkang Biochemical said that it is mainly optimistic about the future development prospects of Jiangxi Weike Division and the photovoltaic film indust.
As a pharmaceutical company, Lvkang Biochemical quickly ushered in the rapid attention and inquiries of supervision for this "cross-border" acti.
On August 3, Lvkang Biochemical received the "Letter of Concern" issued by the exchan.
In the "Letter of Concern", the Shenzhen Stock Exchange required Lvkang Biochemical to explain the reasons and necessity of the company's high premium acquisition under the condition that the underlying asset performance was in loss and the asset-liability ratio was hi.
Talent reserve, market resources, e.
, indicating whether it has sufficient capital investment ability and business integration ability, whether the acquisition decision is prudent and reasonable, whether it is in line with the company's development strategy, whether it can help improve the company's operating quality, and whether there is any hot hy.
The situation of the stock price, and please fully remind the market of the possible risks of the investme.
In addition, the Shenzhen Stock Exchange also requires Lvkang Biochemical to self-examine whether there are insider information leakage, insider trading, e.
, and explain whether relevant personnel have plans to reduce their holdings in the next 6 mont.
According to the data, Lvkang Biochemical is an enterprise focusing on the research and development, production and sales of veterinary dru.
Its business scope covers veterinary premixes, veterinary APIs, food preservatives and other fiel.
The 2021 annual report shows that the company recorded its first loss due to rising cos.
During the reporting period, the company achieved an operating income of 363 million yuan, a year-on-year increase of 193%, and a net profit loss attributable to the parent of 20439 million yuan, a year-on-year decrease of 162
Entering the first quarter of 2022, Lvkang Biochemical's revenue and net profit both fell sharp.
Among them, the operating income was 66871 million yuan, a year-on-year decrease of 306%, and the net profit attributable to the parent continued to lose 9138 million yuan, a year-on-year change from profit to loss, a sharp decline of 471
With the company's "cross-border" photovoltaic share price soaring, shareholder Beijing Kangmin terminated its holding reduction plan ahead of schedu.
It is reported that Beijing Kangminyuan previously planned to reduce its holding of 1 million shares of the company, accounting for 64% of the company's total share capital
The industry believes that, at present, there is a high degree of uncertainty as to whether Lvkang Biochemical can successfully cross the border and whether it can improve the operating performance of the listed compa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
According to industry statistics, no less than 20 companies have announced their entry into the photovoltaic industry since the beginning of this year, with an investment of tens of billions of yu.
There are also some pharmaceutical companies among th.
On August 4, Lvkang Biochemical, a pharmaceutical company in the cross-border photovoltaic industry, won the market's attention by winning the four-link boa.
As of the close on the 3rd, the stock's closing price was 180 yuan, and the stock price hit a new high in nearly 3 years that d.
On the news, on August 1, Lvkang Biochemical announced that it planned to acquire 100% of the equity of the loss-making company Jiangxi Weike at a premium of 632%, and then lay out the photovoltaic film indust.
According to the announcement, Lvkang Biochemical intends to purchase 100% equity of Jiangxi Weike held by Yushan Wanghong Enterprise Management Center (Limited Partnership) and Wang Meijun in cash, with an estimated asset value of 100 million yuan, a premium over its book net assets about 63
According to the data, Jiangxi Weike is mainly engaged in the research and development, production, sales and installation of thin-film composite materials and photovoltaic supporting componen.
The company will have a loss of 6374 million yuan in 2021 and a loss of 8863 million yuan from January to April 2022, with an asset-liability ratio of 9
According to the announcement, the estimated value of 100% equity of Jiangxi Weike is 100 million yuan, and the premium rate is about 63
Regarding the reason for this high premium acquisition, Lvkang Biochemical said that it is mainly optimistic about the future development prospects of Jiangxi Weike Division and the photovoltaic film indust.
As a pharmaceutical company, Lvkang Biochemical quickly ushered in the rapid attention and inquiries of supervision for this "cross-border" acti.
On August 3, Lvkang Biochemical received the "Letter of Concern" issued by the exchan.
In the "Letter of Concern", the Shenzhen Stock Exchange required Lvkang Biochemical to explain the reasons and necessity of the company's high premium acquisition under the condition that the underlying asset performance was in loss and the asset-liability ratio was hi.
Talent reserve, market resources, e.
, indicating whether it has sufficient capital investment ability and business integration ability, whether the acquisition decision is prudent and reasonable, whether it is in line with the company's development strategy, whether it can help improve the company's operating quality, and whether there is any hot hy.
The situation of the stock price, and please fully remind the market of the possible risks of the investme.
In addition, the Shenzhen Stock Exchange also requires Lvkang Biochemical to self-examine whether there are insider information leakage, insider trading, e.
, and explain whether relevant personnel have plans to reduce their holdings in the next 6 mont.
According to the data, Lvkang Biochemical is an enterprise focusing on the research and development, production and sales of veterinary dru.
Its business scope covers veterinary premixes, veterinary APIs, food preservatives and other fiel.
The 2021 annual report shows that the company recorded its first loss due to rising cos.
During the reporting period, the company achieved an operating income of 363 million yuan, a year-on-year increase of 193%, and a net profit loss attributable to the parent of 20439 million yuan, a year-on-year decrease of 162
Entering the first quarter of 2022, Lvkang Biochemical's revenue and net profit both fell sharp.
Among them, the operating income was 66871 million yuan, a year-on-year decrease of 306%, and the net profit attributable to the parent continued to lose 9138 million yuan, a year-on-year change from profit to loss, a sharp decline of 471
With the company's "cross-border" photovoltaic share price soaring, shareholder Beijing Kangmin terminated its holding reduction plan ahead of schedu.
It is reported that Beijing Kangminyuan previously planned to reduce its holding of 1 million shares of the company, accounting for 64% of the company's total share capital
The industry believes that, at present, there is a high degree of uncertainty as to whether Lvkang Biochemical can successfully cross the border and whether it can improve the operating performance of the listed compa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
